Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308 | 0.93 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL15053822 | 0.93 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL8727210 | 0.93 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL748244 | 0.93 | TSHR (0.37) | TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9513085 | 0.91 | TSHR (0.35) | TSHRALDH1A1 | |
| Methane SCHEMBL2179835 | 0.91 | TSHR (0.35) | TSHRALDH1A1 | |
| Methyl Alcohol SCHEMBL9400635 | 0.91 | TSHR (0.35) | TSHRALDH1A1 | |
| SCHEMBL7262572 | 0.91 | TSHR (0.35) | TSHRALDH1A1 | |
| Fluoride SCHEMBL6427102 | 0.91 | TSHR (0.35) | TSHRALDH1A1 | |
| Ethane SCHEMBL10522900 | 0.91 | TSHR (0.35) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123010-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | AVENIR WELLNESS SOLUTIONS INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11938160-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2024-03-26 | — | — | US | disclosed |
| US-11890310-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2024-02-06 | — | — | US | disclosed |
| US-11844763-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2023-12-19 | — | — | US | disclosed |
| US-20230085079-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2023-03-16 | — | — | US | disclosed |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2022-09-08 | — | — | US | disclosed |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-31 | — | — | US | disclosed |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-17 | — | — | US | disclosed |
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-6634575-B2 | Birch bark processing and the isolation of natural products from birch bark | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-10-21 | — | — | US | disclosed |
| US-20030109727-A1 | Isolation of natural products from birch bark | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-06-12 | — | — | US | disclosed |
| US-20020155177-A1 | Process for extracting compounds from plants | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-10-24 | — | — | US | disclosed |
| US-20020114853-A1 | Process for extracting compounds from plants | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-08-22 | — | — | US | disclosed |
| US-20020070167-A1 | Birch bark processing and the isolation of natural products from birch bark | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-06-13 | — | — | US | disclosed |
| EP-1206481-A2 | BIRCH BARK PROCESSING AND THE ISOLATION OF NATURAL PRODUCTS FROM BIRCH BARK | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6392070-B1 | Birch bark processing and the isolation of natural products from birch bark | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-05-21 | — | — | US | disclosed |
| US-20020043577-A1 | Birch bark processing and the isolation of natural products from birch bark | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-04-18 | — | — | US | disclosed |
| WO-2002026343-A2 | PROCESS FOR EXTRACTING COMPOUNDS FROM PLANTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001010885-A2 | BIRCH BARK PROCESSING AND THE ISOLATION OF NATURAL PRODUCTS FROM BIRCH BARK | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844763-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20230085079-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20200246405-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-11890310-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20030109727-A1 | Isolation of natural products from birch bark | ALOX15, ALOX12, ALOX5 | TSHR 4813/4885ALDH1A1 1473/4885 |
| US-11344591-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20220280582-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20240123010-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-11938160-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | TSHR 4585/4885ALDH1A1 4647/4885 |
| US-20020114853-A1 | Process for extracting compounds from plants | ATL3, NPEPPS, NAAA | TSHR 4825/4885ALDH1A1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.